In a landmark OK, FDA green-lights Bristol-Myers' Opdivo for a niche group of metastatic lung cancer patients
Bristol-Myers Squibb $BMY may have lost the long-running battle with Merck $MRK for leading the industry on overall checkpoint revenue, but they are still fighting …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
